Camstech

Camstech Ltd is a UK-based biotechnology company founded in 2014, specializing in the development of novel biochemical sensing technologies for medical diagnostics. The company originated from a vision to commercialize a sensing technology developed by Professor Pankaj Vadgama, who now serves as the Chief Scientific Officer. He is the Director of the IRC in Biomedical Materials and a Professor of Clinical Biochemistry at Queen Mary University of London. The company's CEO, Alex Efimov, is a physicist with an MBA from the University of Cambridge who previously worked as a Technology Transfer Officer at CERN.

The firm's core technology combines a lateral flow assay with an optical readout system to create miniature, multi-analyte point-of-care (PoCT) instruments. This platform provides quantitative results for a wide range of biomarkers, comparable to low-cost strip sensors. A key advancement came in 2015 when Camstech licensed manufacturing technology from CERN, originally used for the Large Hadron Collider (LHC) upgrade, enabling the cost-effective, scalable production of its sensors.

Camstech operates in the point-of-care diagnostics market, addressing the demand for rapid, low-cost, and multiplexed testing solutions. The company graduated from the CERN Business Incubation Centre at Harwell Campus and is now based at the Campus Technology Hub at Daresbury Laboratory. It has received funding from investors including the UK Innovation & Science Seed Fund (UKI2S), Midven, and Innovate UK through an investment accelerator pilot program.

Keywords: biochemical sensing, point-of-care testing, medical diagnostics, biosensors, lateral flow assay, optical readout system, CERN technology, biomarker detection, multi-analyte testing, clinical biochemistry, PoCT instruments, UKI2S, Daresbury Laboratory, Pankaj Vadgama, Alex Efimov, medtech, biotechnology, diagnostics